TEXT OMITTED AND FILED SEPARATELY CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 240.24B-2 LICENSE, DEVELOPMENT AND COOPERATION AGREEMENT THIS LICENSE, DEVELOPMENT, AND COOPERATION AGREEMENT (this "AGREEMENT"), dated as of...License, Development and Cooperation Agreement • March 9th, 2004 • Gen Probe Inc • Services-commercial physical & biological research • New York
AMENDMENT NO. 2 TO LICENSE, DEVELOPMENT AND COOPERATION AGREEMENTLicense, Development and Cooperation Agreement • August 6th, 2009 • Gen Probe Inc • Surgical & medical instruments & apparatus
This Amendment No. 2 (“Amendment No. 2”) is entered into effective as of April 28, 2009 (the “Amendment Effective Date”), pursuant to and amending that certain License, Development and Cooperation Agreement (the “Agreement”) between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) and DiagnoCure, Inc., a company organized under the laws of the Province of Quebec, Canada (“DiagnoCure”). Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
ContractLicense, Development and Cooperation Agreement • November 9th, 2011 • Forest Laboratories Inc • Pharmaceutical preparations
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT AND COOPERATION AGREEMENTLicense, Development and Cooperation Agreement • August 3rd, 2006 • Gen Probe Inc • Services-commercial physical & biological research
This Amendment No. 1 (“Amendment No. 1”) is entered into effective as of May 24, 2006 (the “Amendment Effective Date”), pursuant to and amending that certain License, Development and Cooperation Agreement (the “Agreement”) between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) and DiagnoCure, Inc., a company organized under the laws of the Province of Quebec, Canada (“DiagnoCure”). Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. LICENSE, DEVELOPMENT and COOPERATION AGREEMENT VILAZODONE (EMD 68843) by and between: Merck KGaA and: Genaissance...License, Development and Cooperation Agreement • October 13th, 2004 • Genaissance Pharmaceuticals Inc • Services-commercial physical & biological research
Whereas, MERCK KGAA and GlaxoSmithKline (GSK) have carried out extensive preclinical research and development work and certain clinical studies on VILAZODONE defined below.
